NCT02390375

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 348 (actual)
• Sponsor: Daewon Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of the DW0929 in patients with primary hypercholesterolemia

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	DW-0929	5/10mg
DRUG	DW-0929	10/10mg
DRUG	DW-0929	20/10mg
DRUG	Rosuvastatin	5mg F/U study: DW-0929 5/10mg
DRUG	Rosuvastatin	10mg F/U study: DW-0929 10/10mg
DRUG	Rosuvastatin	20mg F/U study: DW-0929 20/10mg

Timeline

• Start date: 2014-11-01
• Primary completion: 2016-04-01
• Completion: 2016-05-01
• First posted: 2015-03-17
• Last updated: 2016-10-10

Locations

1 site across 1 country: South Korea